Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events across the Ulcerative Colitis Clinical Program

Gary R. Lichtenstein, Gerhard Rogler, Matthew A. Ciorba, Chinyu Su, Gary Chan, Ronald D. Pedersen, Nervin Lawendy, Daniel Quirk, Chudy I. Nduaka, Andrew J. Thorpe, Julian Panés

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events across the Ulcerative Colitis Clinical Program'. Together they form a unique fingerprint.

Medicine & Life Sciences